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Abstract 
PURPOSE. VEGF has been shown to be necessary, but not sufficient alone, for the development of subretinal 
pathologic angiogenesis. In the current study, the influence of placental growth factor (PlGF), a member of the 
VEGF family, in human and experimental choroidal neovascularization (CNV) was investigated. 
METHODS. The presence of VEGF family member mRNA was evaluated by RT-PCR in neovascular membranes 
extracted during surgery. The spatial and temporal pattern of VEGF isoforms and PlGF mRNA expression were 
explored by using the laser capture catapulting technique and RT-PCR in a murine laser-induced model and in 
vitro. PlGF expression was also studied in human donor eyes. The influence of endogenous PlGF was evaluated 
in deficient mice (PlGF-/-) and by antibody-mediated neutralization of the PlGF receptor. 
RESULTS. Human neovascular membranes consistently expressed VEGF-A, -B, and -C; PlGF; and VEGFR-1 
and -2. The VEGF120 isoform mRNA was primarily induced in early stages of angiogenesis in vivo and in vitro. 
PlGF mRNA expression was present in the intact choroid and significantly upregulated during the course of 
experimental CNV. Both deficient PlGF expression in PlGF-/- mice and PlGF receptor neutralization in wild-type 
mice prevented the development of choroidal neovascularization induced by laser. 
CONCLUSIONS. These observations demonstrate the participation of PlGF in experimental CNV. They identify 
therefore PlGF as an additional promising target for ocular antiangiogenic strategies.  
 
Vascular endothelial growth factor type A (VEGF-A, commonly referred to as VEGF) has been implicated in 
several retinal disorders characterized by neovascularization, including the exudative form of age-related 
macular degeneration (AMD).1,2 Several reports have demonstrated the simultaneous presence of VEGF-A and 
its receptor VEGFR-2 (also known as Flk1) in neovascular membranes and in experimental choroidal 
neovascularization (CNV).3-5 These observations have lead to the development of several preclinical studies 
using anti-VEGF strategy, such as anti-VEGF antibody or aptamer.6,7
However, VEGF-A is expressed throughout the normal retina without the development of endothelial cell 
proliferation of vascular leakage8 suggesting that the VEGF system may be only one part of a complex network 
of pro- and antiangiogenic mechanisms operating both under physiologic and pathologic conditions.9 
Furthermore, isolated overexpression of VEGF-A either in photoreceptors or in retinal pigment epithelium of 
transgenic mice does not result in the formation of CNV,10,11 unless some kind of local trauma (i.e., trauma 
associated with sustained release models or subretinal injection of viral vectors) is induced in Bruch's 
membrane.12,13 This indicates that the development of CNV necessitates either a combination of multiple 
proangiogenic growth factors in cooperation with VEGF-A, a simultaneous decrease in the expression of 
antiangiogenic agents (such as demonstrated in vitro for pigment epithelium-derived growth factor-PEDF),14,15 or 
that damage to Bruch's membrane and photoreceptors is a necessary condition. 
The VEGF family, besides VEGF-A, includes also VEGF-B, -C, and -D and placental growth factor (PlGF),16 
and the presence of these proteins has recently been reported in human CNV membranes.17
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PlGF and its receptor Flt1 (also referred to as VEGFR-1) received little attention until a recent report 
demonstrating that although PlGF-deficient mice develop normally, loss of PlGF blocks pathologic angiogenesis 
and vascular leakage in cancer, ischemia, and wound healing.18 In the cornea pellet model, PlGF was as effective 
as VEGF-A in inducing angiogenesis.19 In the retina, PlGF expression was not upregulated by hypoxia,20 but 
PlGF deficiency reduced by 60% the amount of retinal neovascularization in the retinopathy of prematurity 
(ROP) model,18 and PlGF was proangiogenic on retinal endothelial cells.21 Finally, PlGF was detected in the 
vitreous and in the neovascular membranes in proliferative diabetic retinopathy.22
The potential involvement of PlGF has not been investigated in human or experimental CNV. 
In the present study, in addition to VEGF-A, human choroidal neovascular membranes excised during surgery 
for macular translocation (end-stage disease) also expressed PlGF, VEGF-B and -C, and VEGFR-1 and -2 
mRNAs. The spatial and temporal expression profiles of VEGF isoforms and of PlGF were further evaluated by 
RT-PCR in a murine laser-induced CNV model. To characterize the relative contribution of PlGF to the 
development of experimental choroidal angiogenesis, we induced subretinal neovascularization in PlGF-
deficient mice (PlGF-/-), in wild-type (WT) control mice, and in mice treated with an inhibitor of PlGF receptor. 
 
TABLE 1: RT-PCR Parameters 
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m, mouse; h, human. * 45 Cycles for LPC 
 
MATERIALS AND METHODS 
RT-PCR Analysis of Neovascular Membranes 
Four consecutive submacular CNV specimens were completely removed during surgery for 360° macular 
translocation performed on patients with exudative AMD, either not amenable to conventional 
laser/photodynamic therapy (presence of occult neovessels or submacular bleeding) or in one patient, owing to a 
severe recurrence a few months after successful medical treatment. The neovascular membranes were snap 
frozen in liquid nitrogen and stored at -80°C. The methods conformed to the provisions of the Declaration of 
Helsinki for research involving human subjects. Ten human donor eyes (from the Cornea Bank, Liège, Belgium) 
were used to evaluate the expression of PlGF in intact neural retina and RPE-choroid. 
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CNV was induced in mice by multiple argon laser burns, as previously described.23 Animals were killed at days 
3, 5, 10, 14, 20, and 40, and the eyes were enucleated. The posterior segments (neural retina and RPE-choroid 
complex) were dissected and immediately frozen in liquid nitrogen. 
The frozen tissues were pulverized (Dismembrator; B. Braun Biotech International, GmbH, Melsungen, 
Germany), and total RNA was extracted with a kit (RNeasy; Qiagen, Paris, France), according to the 
manufacturer's protocol. 28S rRNA was amplified with an 10-ng aliquot of total RNA (for tissues) or 1 µL of 
total RNA (laser pressure catapulting [LPC] samples) using an amplification kit (GeneAmp Thermostable rTth 
reverse transcriptase RNA PCR kit; Applied Biosystems, Foster City, CA) and two pairs of primers (Eurogentec, 
Liège, Belgium) with the oligonucleotide sequences shown in Table 1. For VEGF-A, a synthetic RNA (CTR1, 
internal control) giving rise to a 311-bp fragment was incorporated in the experiment involving aortic rings. 
Reverse transcription was performed at 70°C for 15 minutes followed by 2 minutes of incubation at 95°C for 
denaturation of RNA-DNA heteroduplexes. Amplification began with 15 seconds at 94°C, 20 seconds at 60°C, 
and 10 seconds at 72°C. RT-PCR products were resolved on 2% agarose gels and analyzed with a fluorescence 
imager (Fluor-S Multi-Imager; Bio-Rad, Hertfordshire, UK) after staining with ethidium bromide (FMC 
BioProducts, Philadelphia, PA). 
Laser Pressure Catapulting 
To evaluate the spatial and temporal pattern of VEGF-A and PlGF expression in experimental CNV, eyes were 
enucleated at selected intervals (days 3, 5, and 14) after laser induction, embedded in OCT compound (Tissue 
Tek; Miles Laboratories, Naperville, IL), and frozen in liquid nitrogen. Serial frozen sections (n = 8-10) were 
mounted directly onto 1.35-mm thin polyethylene foil (Palm, Wolfratshausen, Germany). The system (Robot-
Microbeam; Palm) focused the laser (337 nm) on the specimen enabling the catapulting of the entire selected 
area into the microfuge cap. The subretinal CNV area (see Fig. 2A, inside the dotted line) and an adjacent intact 
chorioretinal zone (control) were microdissected separately on frozen sections (10 µm thick). The specimens 
were covered with 100 µL lysis buffer and total RNA isolation was performed with an RNA isolation kit 
(PUREscript; Biozym, Landgraaf, The Netherlands) according to the manufacturer's protocol. Total RNA was 
dissolved in a 10-µL RNA hydration solution supplied by the manufacturer, and RT-PCR was performed as 
previously described.23
Genetically Modified Mice 
We used the progeny of heterozygous breeding pairs of mice with targeted disruption of PlGF, as described.18 
Brothers and sisters from the same litter were intercrossed by brother-sister mating to obtain homozygous 
offspring genotyped by RT-PCR. Two- to 5-month-old pigmented PlGF-deficient mice (PlGF-/-) and the 
corresponding WT mice (PlGF+/+) of either sex were used in experiments in which neovascular membranes were 
quantified. The animals (five or more in each group) used in this study were maintained in a 12-hour light- dark 
cycle and had free access to food and water. All animal experiments were performed in compliance with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
Murine Model of Laser-Induced CNV 
CNV was induced in mice by four burns (at the 6, 9, 12, and 3 o'clock positions around the optic disc) using a 
green argon laser (532 nm; 50-µm diameter spot size; 0.05-second duration; 400 mW) as previously 
described.23,24 The eyes were enucleated at day 14, embedded in OCT compound (Tissue Tek; Miles 
Laboratories), and frozen in liquid nitrogen for cryostat sectioning. To quantify CNV, frozen serial sections were 
cut throughout the entire extent of each burn, and the thickest region (minimum of four per lesion) was used for 
the quantification.23,24 Using a computer-assisted image analysis system (Olympus Micro Image version 3.0 for 
Windows 95/NT; Olympus Optical Co. Europe, Hamburg, Germany), neovascularization was estimated by the 
ratio (B-C) of the thickness from the bottom of the pigmented choroidal layer to the top of the neovascular 
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FIGURE 1: VEGF family mRNA expression in exudative AMD. Representative example of VEGF-A, -B, -C; PlGF; VEGFR-1 
and -2 mRNA expression in surgically extracted choroidal neovascular membranes of four patients (subjects 1-4) with aggressive exudative 
AMD. Total RNA (approximately 10 ng) was subjected to RT-PCR. The 28S rRNA was used to assess the total amount of RNA loaded. 
Apparent differences in the pattern of mRNA expression in the CNV of different patients were not quantified. M, molecular marker. Right: 
PCR products size (in base pairs; see also Table 1). 
 
Neutralization of PlGF Receptor 
To evaluate whether inhibition of the PlGF pathway would inhibit the development of laser-induced CNV, WT 
mice were intraperitoneally injected with 500 µg monoclonal rat anti-mouse-Flt1 (clone MF-1, a generous gift of 
Daniel J. Hicklin, ImClone Systems Inc., New York, NY). Control mice were similarly injected three times per 
week with an equal dose of rat immunoglobulins (IgG; Sigma-Aldrich, Bornem, Belgium).25 At day 14, mice 
treated with anti-Flt1 and controls were anesthetized and intravenously perfused with 0.3 mL phosphate-buffered 
saline (PBS) containing 50 mg/mL fluorescein-labeled dextran (2 x 10 average molecular weight; Sigma-
Aldrich), as previously described.26,27 The eyes were removed and either embedded in OCT compound (for B-C 
ratio evaluation on frozen serial sections) or dissected to obtain choroidal flatmounts embedded in aqueous 
mounting medium (Aquamount; Sigma-Aldrich). Flatmounts were examined by fluorescence microscope 
(Axiovert 135; Carl Zeiss Meditech, Zaventem, Belgium) and laser scanning confocal microscope (Bio-Rad), 
and images were digitized. Image-analysis software (Photoshop 5.0; Adobe Systems, Mountain View, CA) was 
used to measure the total area of hyperfluorescence associated with each laser impact. 
Aortic Ring Model 
Mice aortic expiant cultures were prepared as described.28 Briefly, ring-shaped expiants of mouse aorta were 
embedded in a rat tail interstitial collagen (type I) gel (Collagen R; Serva, Heidelberg, Germany) and allowed to 
gel in cylindrical agarose wells. Aortic rings were maintained at 37°C in 6 mL of MCDB131 (Life Technologies, 
Paisley, Scotland) supplemented with 25 mM NaHCO3, 2.5% mouse serum, 1% glutamine, 100 U/mL penicillin, 
and 100 µg/mL streptomycin. The endothelial origin of migrating cells was verified by Dil-Ac-LDL (Sigma-
Aldrich) incorporation in the aorta ring before it was embedded in collagen gel (10 µg/mL for 4 hours at 37°C). 
At day 7, aortic rings (see Fig. 2C, inside the dotted line) were removed from the collagen gel and frozen 
individually in liquid nitrogen. Migrating endothelial cells from three mice were removed by centrifugation after 
treatment of the collagen gel with 1 mg/mL collagenase A (Sigma) for 10 minutes at 37°C, pooled, and stored in 
liquid nitrogen until RT-PCR. 
Immunohistochemistry 
Cryostat sections (5 µm thick) were fixed in paraformaldehyde 1% in 0.07 M phosphate-buffered saline (PBS; 
pH 7.0) for 5 minutes or in acetone for 10 minutes at room temperature and then incubated with the primary 
antibody. Antibodies raised against type IV collagen (guinea pig polyclonal, produced in our laboratory; diluted 
1/100), mouse platelet- endothelial cell adhesion molecule (PECAM; rat monoclonal, PharMingen, San Diego, 
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CA; diluted 1:20), VEGF (rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:100), and 
murine PlGF (rat monoclonal, R&D Systems, Abingdon, UK; diluted 1:50) were incubated for 1 hour at room 
temperature. The sections were washed in PBS (three times for 10 minutes each), and appropriate secondary 
antibody conjugated to horseradish peroxidase (HRP), fluorescein-isothiocyanate (FITC), or tetramethyl-
rhodamine isothiocyanate (TRITC) was added: goat anti-rabbit IgG (Dako, Glostrup, Denmark; diluted 1:400), 
rabbit anti-rat IgG (Sigma-Aldrich, diluted 1:40; Dako, diluted 1:100) monoclonal anti-guinea pig IgG (Sigma-
Aldrich; diluted 1:40) were applied for 30 minutes. For staining of PlGF and VEGF, 1 drop of 3-amino-9-
ethylcarbazole (AEC+; Dako) was added, and sections were counterstained for 1 minute in hematoxylin. For 
immunofluorescence staining, after three washes in PBS for 10 minutes each and a final rinse in 10 mM Tris-
HCl buffer (pH 8.8), labeling was analyzed under an inverted microscope equipped with epifluorescence optics. 
Specificity of staining (not shown) was assessed either by substitution of nonimmune serum for primary 
antibody, or for VEGF, by incubation with excess of blocking peptide (sc-152P; Santa Cruz Biotechnology). 
Statistical Analysis 
Data were analyzed for statistical significance (P < 0.05) on computer (Prism 3.0; GraphPad, San Diego, CA). 
The Mann-Whitney, Wilcoxon, and χ2 test (with Yates' correction) were used. 
RESULTS 
VEGF Family Expression Profile in Human Neovascular Membranes 
VEGF-A, -B, and -C; PlGF; VEGFR-1 and -2 mRNA were detected in all CNV specimens obtained during 
surgery (Fig. 1). VEGF-D and VEGFR-3 were detected inconsistently (not shown). These neovascular 
membranes shared in common an aggressive history and probably represent a late stage of macular disease. 
Therefore, to evaluate more precisely the early spatial and temporal expression profiles of VEGF-A isoforms and 
of PlGF, RT-PCR analysis was applied on laser-induced murine neovascular choroidal membranes at different 
end points after laser treatment. 
RT-PCR Study of VEGF Isoforms 
VEGF protein was immunohistochemically detected in the intact neural retina, in the choroid, and in the 
neovascular membrane as previously described29 (Fig. 2A). We applied LPC technology to evaluate the pattern 
of VEGF-A expression specifically in the CNV compared with adjacent intact neural retina. The expression of 
the three murine VEGF-A isoforms mRNAs (VEGF120, VEGF164, and VEGF188) was evident in the intact neural 
retina and choroid (Fig. 2B). The expression of the VEGF120 isoform mRNA was predominant in early stages of 
CNV induced by laser treatment. Because the specific expression of VEGF120 mRNA had not been previously 
associated with the induction of murine endothelial cell proliferation, we performed an RT-PCR analysis in 
another unrelated murine model of angiogenesis, the aortic ring model. That model enables the separation of the 
parental aortic segment from the endothelial cells (Fig. 2D, EC) dividing and migrating in the collagen gel (Fig. 
2C). VEGF120 mRNA was also preferentially expressed in proliferating endothelial cells migrating in the gel, 
whereas both VEGF120 and VEGF164 were expressed in the parental aortic rings (Fig. 2D). 
RT-PCR Study of PlGF 
Unlike VEGF-A, PlGF protein was not detected in murine neural retina. It colocalized with collagen type IV and 
appeared to be concentrated in the choroidal layer and at the leading edge of the CNV (Figs. 3A-D). To evaluate 
the spatial pattern of PlGF mRNA expression, we performed RT-PCR on intact neural retina, intact choroid, and 
CNV after LPC (Fig. 3E). This confirmed the observations obtained at the protein level. PlGF mRNA was 
expressed in the intact choroid, was almost undetectable in neural retina, and was expressed in the CNV. The 
apparent low expression of PlGF mRNA at day 3 after laser treatment could correspond to limited amounts of 
neovascular elements that can be extracted by LPC at that early stage. In intact human donor eyes, PlGF mRNA 
was also preferentially expressed in the choroidal layer (Fig. 3F). To evaluate semi-quantitatively the temporal 
change in PlGF mRNA expression (which is not reliable with the LPC method), RT-PCR analysis was 
performed on mouse ocular posterior segments subjected to a larger number of laser-induced ruptures of Bruch's 
membrane (Figs. 3G, 3H). This demonstrated a statistically significant upregulation of PlGF expression during 
initial CNV development at days 3 and 5, with a return to basal expression levels after day 10 (coinciding with 
the period of CNV stabilization). 
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FIGURE 2: VEGF120 is the main isoform expressed in early stages of murine CNV (A, B) and in the aortic ring 
model (C, D). (A) VEGF-A protein was immunostained both in the CNV and in the neural retina at day 14 after laser treatment. (B) LPC 
followed by RT-PCR analysis of VEGF-A isoforms in microdissected choroidal neovessels (A, dotted line) growing in the subretinal space 
(CNV), in adjacent intact retinal tissue (R) and in normal choroid (Ch) from days 3 to 14. VEGF120 isoform (275 bp) appeared to be primarily 
expressed in these early stages of murine CNV development. (C) Photomicrograph of collagen-embedded aortic ring expiant isolated from 
WT mice and cultured for 7 days in autologous serum. (D) RT-PCR analysis of parental rings (dotted line) and endothelial cells (EC) showed 
the predominant expression of VEGF120 isoform () in proliferating endothelium, whereas the two major isoforms (VEGF120 and VEGFl64) 
were expressed in the parental rings. The position of the synthetic internal control RNA for VEGF is at 311 bp, VEGF120 at 275 bp, VEGFl64 
at 407 bp, and VEGF188 at 479 bp. M, molecular marker. Original magnification: (A, C) x 200. 
 
 
CNV In Vivo 
To determine whether the absence of PlGF influenced CNV in vivo, we first evaluated the efficiency of CNV 
lesion development in PlGF deficient and WT mice. In PlGF-/- mice, most of the lesions were detectable only 
indirectly through the trauma observed in the photoreceptor layer, whereas in PlGF+/+ control specimens, CNV 
development with endothelial (identified by anti-PECAM immunostaining) and pigmented cells was clearly 
identified (Figs. 4A-D). Choroidal newly formed microvessels growing over the plane of RPE were present in 
81.2% of the laser-induced lesions in PlGF+/+ versus 18.5% in PlGF-/- mice (χ2Y = 11.2, P < 0.001). Severity of 
neovascularization was then estimated histologically, by measuring on serial sections the maximum height of the 
lesion above the choroidal layer observed in neighboring intact zones, as previously described. This was 
quantified by determining the B-C ratio between total thickness of lesions (B), from the bottom of the choroid to 
the top of the neovascular area to the thickness of adjacent normal choroid (C), and a 70% reduction of the B-C 
ratio was consistently observed in PlGF-deficient mice (P < 0.001) compared with WT mice (Fig. 4E). 
Compared with control mice treated with IgG, anti-Fltl-treated mice developed significantly (P < 0.001) smaller 
CNV. This was evidenced both by measuring CNV surface on choroidal flatmounts (60% reduction) and by 
calculating the B-C ratio (40% reduction) on frozen sections (Fig. 5). 
 
 
Published in: Investigative Ophthalmology & Visual Science (2003), vol.44, iss.7, pp. 3186-3193 
Status: Postprint (Author’s version) 
FIGURE 3: Immunolocalization and mRNA expression of PlGF in laser-induced CNV. (A-C) Immunofluorescence 
labeling of PlGF (red) and colocalization with collagen type IV (green) at day 14 after laser-induced CNV. (D) PlGF protein was 
immunostained in the neovascular leading edge and in the choroidal (Ch) layer (yellow arrows) Ret, retina. (E) LPC followed by RT-PCR 
analysis of intact choroid (Ch), microdissected choroidal neovessels (dotted line) growing in the subretinal space (CNV), and adjacent intact 
neural retina (R) at day 3, 5, and 14. The spatial profile of PlGF mRNA paralleled the localization of the protein, with expression in the intact 
choroidal layer and in the CNV, and almost undetectable expression in neural retina. (F) PlGF mRNA was also present in human normal 
posterior segments, with a predominant expression in the RPE-choroid complex (Ch). (G) Representative gel of PlGF and 28S mRNA 
expression evaluated on the entire ocular posterior segment by RT-PCR at different end points (day 3-40) after laser-induced trauma in mice. 
(H) The histogram corresponds to the densitometric quantification of PlGF mRNA normalized to the 28S signal (n = 12). There was a 
statistically significant induction of PlGF mRNA at days 3 and 5 after laser treatment, compared with the level of PlGF mRNA expressed at 
day 0. The positions of murine and human PlGF mRNA are at 130 and 164 bp, respectively. **P < 0.01, ***P < 0.001; error bars, SE; M, 
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FIGURE 4: Absence of PlGF prevented the development of CNV. (A) Hematoxylin-eosin staining of a representative area of 
CNV at the site of laser-induced trauma and (B) immunofluorescence labeling of neovessels in PlGF+/+ mice. New vessels were detected with 
colocalization of anti-mouse anti-collagen type IV antibody (red) and anti-mouse anti-PECAM antibody (green). (C, D) Almost complete 
absence of neovascularization was visible in PlGF-/- mice both in terms of neovascular volume and lateral extension. (E) The neovascular 
reaction was determined with computer-assisted image analysis by evaluating the B-C ratio, as previously described23,24 at day 14 after laser 
injury of the Bruch's membrane in WT mice and in the limited number of laser impact sites developing a measurable reaction in PlGF-
deficient mice. The neural retina (Ret) and choroidal layer (Ch) are indicated. Arrows: the neovascular area. Original magnification: (A, C) 
x200: (B, D) x400; error bars, SE. 
 
DISCUSSION 
We report here that, in addition to VEGF-A, other members of the VEGF family and their receptors are also 
expressed in late stages of human exudative AMD. This study completes a previous report demonstrating, by 
immunohistochemistry, the presence of VEGF-B and -C, and PlGF proteins in human choroidal neovascular 
membranes.17 PlGF mRNA was also expressed in intact murine and human choroidal layer. The redundancy in 
expression of angiogenic factors has been associated with aggressive vascular remodeling and/or tumor 
progression.30 Our observations suggest that, as in other tissues subjected to pathologic angiogenesis, CNV 
formation is the result of a complex balance of pro- and antiangiogenic influences not limited to isolated 
overexpression of VEGF-A. Although the three VEGF-A major isoforms were expressed at a basal rate in intact 
murine choroidal layer and neural retina, VEGF120 mRNA was the isoform primarily induced in early stages of 
experimental murine CNV (extracted by LPC) and, in vitro, in proliferating endothelial cells migrating from an 
aortic ring segment. It is obviously difficult to evaluate the relevance of these results to the situation in the 
human eye. The three VEGF-A isoforms were clearly expressed in human neovascular membranes extracted at a 
late stage, during macular translocation. Furthermore, the murine model of CNV represents merely a wound-
healing response, and the aortic ring model is an in vitro assay unrelated to ocular neovascularization. Similar 
observations in two completely different models make attractive the alternative hypothesis that a specific VEGF-
A isoform (not necessarily VEGF120) may be selectively expressed during the initiation of human CNV. 
Complete data are lacking to appreciate definitively the relative importance of each member of the VEGF family 
in the development of exudative AMD. Animals with systemic disruption of candidate genes are lethal, and mice 
with inducible silencing of the VEGF-A gene in the posterior segment have not yet been produced. The 
importance of VEGF-A has been recognized based on the demonstration that VEGF mRNA and protein were 
present in pathologic specimens,3 induced by hypoxia in ischemic retinopathies31,32 and on the observations that 
therapeutic strategies aiming at inhibiting VEGF-A (through repeated injections of a blocking antibody or 
through blockade of its receptor) reduced the development of CNV.6,7 However, experimentally, blockade of a 
single player in the complex spectrum of angiogenic actors is usually sufficient to significantly inhibit pathologic 
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neovascularization.33 Furthermore, although VEGF expression is probably necessary, isolated overexpression of 
VEGF is not sufficient for the development of CNV growing under the retina, suggesting the involvement of 
other proangiogenic mechanisms.10,11 We investigated therefore the influence of PlGF on the development of 
experimental CNV, because (1) PlGF expression was present both in human and experimental CNV (this study) 
and (2) PlGF-deficient mice, contrary to VEGF-deficient animals, which do not survive, develop normally and 
demonstrate an abnormal phenotype in various pathologic conditions.18
PlGF deficiency or PlGF receptor neutralization both induced a very significant reduction in the incidence and in 
the severity of laser-induced CNV compared with control animals. 
FIGURE 5: Inhibition of CNV with anti-Fltl antibody. After induction of CNV, WT mice were injected three times 
a week with anti-Fltl antibody (C, D) or control IgG (A, B). Mice treated with anti-Fltl showed CNV lesions that were smaller 
than those in controls both on choroidal flat-mounts examined by fluorescence microscopy (A, C) and on frozen sections counterstained with 
hematoxylin-eosin (B, D). This was quantified by measuring CNV surface (E) and calculating the B-C ratio (F), and a statistically significant 
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The resistance of PIGF-deficient mice to pathologic angiogenesis is in accordance with previously published 
results in hypoxic retina, in an aortic ring model and in cancer.18 PlGF could enhance angiogenesis on its own 
through activation of VEGFR-1,19 by forming heterodimers with VEGF-A,34 or by displacing VEGF-A from 
VEGFR-1.35 PlGF could also mobilize bone-marrow- derived cells and inflammatory cells.18,25 The influence of 
inflammatory components in AMD and in experimental CNV has recently been pointed out by different 
groups.23,36,37 Furthermore, circulating angioblasts were recently shown to contribute to ischemic retinal 
neovascularization.38 The precise mechanisms in the eye obviously need further evaluation. Nevertheless, 
together with the pattern of PlGF mRNA expression obtained in experimental CNV and in surgically extracted 
neovascular membranes, our observations in PIGF-deficient mice suggest a participation of PlGF and its receptor 
Flt1 in the development of exudative AMD. 
The efficacy of VEGF blockade in angiogenesis inhibition is not in dispute, and there is no doubt that VEGF 
and/or its receptors are currently a promising potential target for antiangiogenesis therapy. Our neutralization 
experiment with anti-Flt1 antibody blocked the interactions of PlGF but also of other Flt1 ligands, such as 
VEGF-A or -B.16 In contrast, a recent study demonstrated in a tumoral model that combined inhibition of 
VEGFR-1 and -2 was more efficient than a single approach in inhibiting VEGF effects.39 Moreover, a recent 
study demonstrated that VEGF had neuroprotective and neuroregenerative effects on the retina.40                         
Our observations could therefore be of importance not only for a better understanding of CNV physiopathology 
but also for the treatment of the exudative form of AMD, especially in view of the unavailability of any data 
concerning the safety of long-term VEGF absence on retinal biology. 
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